Estimating the burden of adult hospitalized RSV infection including special populations
- PMID: 35667912
- PMCID: PMC10642722
- DOI: 10.1016/j.vaccine.2022.05.077
Estimating the burden of adult hospitalized RSV infection including special populations
Erratum in
-
Corrigendum to "Estimating the burden of adult hospitalized RSV infection including special populations". [Vaccine 40(31) (2022) 4121-4127].Vaccine. 2022 Oct 6;40(42):6187. doi: 10.1016/j.vaccine.2022.09.027. Epub 2022 Sep 10. Vaccine. 2022. PMID: 36100491 No abstract available.
Abstract
Background: Numerous studies in the U.S. have made estimates of the RSV burden among adults that vary widely due to differences in methodology, reliance on influenza surveillance, which does not adequately capture all RSV clinical symptoms, and lack of diagnostic methods to identify RSV when viral loads are low. Nevertheless, accurate burden estimates can inform healthcare planning, resource allocation and potentially, RSV vaccine policy.
Methods: A simple method combined with statewide and local hospitalization, medical record and U.S. Census data were used to estimate population-based RSV hospitalization burden among adults ages 18-64 years, ≥65 years, and including immunocompetent, immunocompromised and pregnant individuals during 2015-2018 for Allegheny County, Pennsylvania. Economic burden of hospitalization was estimated using state-provided average hospitalization charges for comparisons across patient groups.
Results: The largest burden was borne by adults ≥ 65 years of age whose rates per 100,000 population of that age group (939/100,000) were 7.0-9.0 times those of adults 18-64 years of age (118/100,000). Immunosuppressed patients bore the greatest relative burden of RSV hospitalizations (1,288-1,562/100,000 immunosuppressed individuals). RSV burden ranged from 0 to 808/100,000 pregnant women. Average total charges for RSV hospitalization in Allegheny County across all adults increased from $39 million in 2015-2016 to $57 million in 2016-2017 to $89 million in 2017-2018, due to both increased average charges for an acute respiratory hospitalization and increased numbers of RSV cases.
Conclusions: These RSV burden estimates add to the body of knowledge to guide public health policy makers and offer a method for simply and easily producing population-based burden estimates.
Keywords: Acute respiratory illness; Adults; RSV burden; Retrospective cohort study.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MPN reports an investigator-initiated grant from Merck & Co. outside the submitted work. RKZ and MPN report an investigator-initiated grant from Sanofi Pasteur outside the submitted work.
References
-
- Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV). Updated 12/18/2020. Accessed 12/10/2021, https://www.cdc.gov/rsv/research/us-surveillance.html
-
- Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352 (17):1749–59. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
